These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12149193)

  • 1. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
    Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G
    Blood; 2002 Aug; 100(4):1168-71. PubMed ID: 12149193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
    Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G
    Clin Lymphoma; 2003 Jun; 4(1):32-5. PubMed ID: 12837152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
    Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G
    Blood; 2001 Sep; 98(5):1614-5. PubMed ID: 11520815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
    Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
    Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
    Zangari M; Saghafifar F; Anaissie E; Badros A; Desikan R; Fassas A; Mehta P; Morris C; Toor A; Whitfield D; Siegel E; Barlogie B; Fink L; Tricot G
    Blood Coagul Fibrinolysis; 2002 Apr; 13(3):187-92. PubMed ID: 11943931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
    Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou M; Mitsouli Ch; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A;
    Ann Oncol; 2004 Jan; 15(1):134-8. PubMed ID: 14679133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
    Baz R; Li L; Kottke-Marchant K; Srkalovic G; McGowan B; Yiannaki E; Karam MA; Faiman B; Jawde RA; Andresen S; Zeldis J; Hussein MA
    Mayo Clin Proc; 2005 Dec; 80(12):1568-74. PubMed ID: 16342649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
    Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE
    J Clin Oncol; 2002 Nov; 20(21):4319-23. PubMed ID: 12409330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
    Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G
    J Clin Oncol; 2003 Jul; 21(14):2732-9. PubMed ID: 12860952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.
    Dimopoulos MA; Hamilos G; Zomas A; Gika D; Efstathiou E; Grigoraki V; Poziopoulos C; Xilouri I; Zorzou MP; Anagnostopoulos N; Anagnostopoulos A
    Hematol J; 2004; 5(2):112-7. PubMed ID: 15048060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
    Badros A; Morris C; Zangari M; Barlogie B; Tricot G
    Leuk Lymphoma; 2002 Jun; 43(6):1267-71. PubMed ID: 12152995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
    Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdrè L; Palareti G; Masini L; Tura S; Baccarani M
    Blood; 2002 Sep; 100(6):2272-3. PubMed ID: 12229885
    [No Abstract]   [Full Text] [Related]  

  • 17. Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy.
    Jeng WJ; Kuo MC; Shih LY; Chu PH
    Int J Hematol; 2008 Jun; 87(5):542-544. PubMed ID: 18414984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide and dexamethasone: therapy for multiple myeloma.
    Kumar S; Rajkumar SV
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First line and salvage therapy with total therapy 3-based treatment for multiple myeloma- an extended single center experience.
    Muchtar E; Ram R; Raanani P; Yeshurun M; Oniashvili N; Shpilberg O; Magen H
    Leuk Res; 2014 Dec; 38(12):1401-6. PubMed ID: 25060304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
    Caravita T; Siniscalchi A; Tendas A; Cupelli L; Ales M; Perrotti A; Niscola P; de Fabritiis P
    Ann Hematol; 2011 Jan; 90(1):115-6. PubMed ID: 20422414
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.